United States Patent and Trademark Office
-
Artificial Intelligence, BioPharma, Legal
DeepMind has unlocked protein-based medicine – what does that mean for drug patents?
One of science’s great puzzles is being solved by artificial intelligence and the answers shared freely on the internet. How can life sciences companies make the most of DeepMind’s discoveries while protecting their own?
-
USPTO agrees to Amgen’s petition to review Alexion’s patents on rare disease drug
Shares of Alexion fell more than 11 percent Friday as the office instituted an inter partes review for the drug, Soliris, in the blood disorder paroxysmal nocturnal hemoglobinuria.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.